IL224225B - Liquid formulation of long-acting human growth hormone conjugate - Google Patents
Liquid formulation of long-acting human growth hormone conjugateInfo
- Publication number
- IL224225B IL224225B IL224225A IL22422513A IL224225B IL 224225 B IL224225 B IL 224225B IL 224225 A IL224225 A IL 224225A IL 22422513 A IL22422513 A IL 22422513A IL 224225 B IL224225 B IL 224225B
- Authority
- IL
- Israel
- Prior art keywords
- long
- growth hormone
- liquid formulation
- human growth
- hormone conjugate
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title 1
- 108010000521 Human Growth Hormone Proteins 0.000 title 1
- 239000000854 Human Growth Hormone Substances 0.000 title 1
- 239000012669 liquid formulation Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100067796A KR101337797B1 (ko) | 2010-07-14 | 2010-07-14 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
| PCT/KR2011/005194 WO2012008779A2 (en) | 2010-07-14 | 2011-07-14 | A liquid formulation of long-acting human growth hormone conjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL224225B true IL224225B (en) | 2018-07-31 |
Family
ID=45469941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL224225A IL224225B (en) | 2010-07-14 | 2013-01-14 | Liquid formulation of long-acting human growth hormone conjugate |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9061072B2 (https=) |
| EP (1) | EP2593084B1 (https=) |
| JP (1) | JP5946448B2 (https=) |
| KR (1) | KR101337797B1 (https=) |
| AR (2) | AR082223A1 (https=) |
| AU (1) | AU2011277203B2 (https=) |
| BR (1) | BR112013000902A2 (https=) |
| CA (1) | CA2805228C (https=) |
| ES (1) | ES2673022T3 (https=) |
| IL (1) | IL224225B (https=) |
| RU (1) | RU2623026C2 (https=) |
| TW (1) | TWI459961B (https=) |
| WO (1) | WO2012008779A2 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2607365C2 (ru) | 2011-06-17 | 2017-01-10 | Ханми Сайенс Ко., Лтд. | Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| US10064951B2 (en) * | 2012-03-30 | 2018-09-04 | Hanmi Science Co., Ltd. | Liquid formulation of highly concentrated long-acting human growth hormone conjugate |
| AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| WO2014073842A1 (en) | 2012-11-06 | 2014-05-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| US20160017017A1 (en) | 2013-03-11 | 2016-01-21 | Novo Nordisk Healthcare Ag | Growth Hormone Compounds |
| CN105229035A (zh) * | 2013-03-11 | 2016-01-06 | 诺和诺德保健股份有限公司 | 生长激素化合物 |
| WO2014144549A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Factor ix polypeptide formulations |
| AR096890A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
| EP3689335A1 (en) | 2013-09-27 | 2020-08-05 | Hanmi Pharm. Co., Ltd. | Sustained type human growth hormone preparation |
| MX387560B (es) * | 2014-03-31 | 2025-03-18 | Hanmi Pharmaceutical Co Ltd | Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina. |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| EP3230309B1 (en) * | 2014-12-10 | 2023-03-29 | OPKO Biologics Ltd. | Methods of producing long acting ctp-modified growth hormone polypeptides |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| US9744239B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| ES2784603T3 (es) | 2015-06-02 | 2020-09-29 | Novo Nordisk As | Insulinas con extensiones recombinantes polares |
| DK3347403T3 (da) | 2015-09-11 | 2020-06-29 | Dow Global Technologies Llc | Polyalkoxyfedtforbindelse |
| DK3347031T3 (da) | 2015-09-11 | 2021-04-26 | Nutrition & Biosciences Usa 1 Llc | Sammensætning, der omfatter et protein og en polyalkoxyfedtforbindelse |
| TW202446416A (zh) * | 2015-09-24 | 2024-12-01 | 美商拜奧馬林製藥公司 | 腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物 |
| EP3355931B1 (en) | 2015-10-01 | 2024-06-26 | Novo Nordisk A/S | Protein conjugates |
| KR20170079409A (ko) * | 2015-12-30 | 2017-07-10 | 한미약품 주식회사 | 지속형 인간 성장 호르몬 결합체의 신규 액상 제제 |
| JP2020513019A (ja) | 2017-04-05 | 2020-04-30 | ノヴォ ノルディスク アー／エス | オリゴマー伸長インスリン−Ｆｃコンジュゲート |
| WO2021085518A1 (ja) * | 2019-10-30 | 2021-05-06 | Ｊｃｒファーマ株式会社 | 血清アルブミンと成長ホルモンの融合蛋白質を含有する水性医薬組成物 |
| US12196531B2 (en) | 2020-07-17 | 2025-01-14 | ProtectEd Solutions LLC | Protective cabinet |
| MX2024006318A (es) * | 2021-11-26 | 2024-08-14 | Genexine Inc | Formulacion para administracion de alta concentracion de proteina de fusion de hormona del crecimiento. |
| CN120475959A (zh) * | 2022-12-23 | 2025-08-12 | 韩美药品株式会社 | 包含免疫活性白细胞介素2类似物缀合物的制剂 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981485A (en) * | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
| SE9201073D0 (sv) | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
| DK0955062T3 (da) * | 1992-07-31 | 2007-09-17 | Genentech Inc | Vandig formulering indeholdende humant væksthormon |
| US5519253A (en) * | 1993-09-07 | 1996-05-21 | Delco Electronics Corp. | Coaxial switch module |
| US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| JP3723857B2 (ja) * | 1998-02-04 | 2005-12-07 | 日本ケミカルリサーチ株式会社 | ヒト成長ホルモン含有水性医薬組成物 |
| US7754855B1 (en) * | 1999-07-13 | 2010-07-13 | Bolder Biotechnology, Inc. | Immunoglobulin fusion proteins |
| GB2371227A (en) * | 2001-01-10 | 2002-07-24 | Grandis Biotech Gmbh | Crystallisation - resistant aqueous growth hormone formulations |
| US20060183197A1 (en) * | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
| US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| KR100537260B1 (ko) * | 2003-09-03 | 2005-12-19 | 한미약품 주식회사 | 인간 성장 호르몬의 안정화된 액상 제제용 조성물 |
| ES2383300T3 (es) | 2003-11-13 | 2012-06-20 | Hanmi Holdings Co., Ltd | Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación |
| WO2005063298A1 (en) * | 2003-12-23 | 2005-07-14 | Pharmacia Corporation | Stable growth hormone liquid formulation |
| WO2006048689A2 (en) * | 2004-11-08 | 2006-05-11 | Encesys Limited | Integrated circuits and power supplies |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| KR100739728B1 (ko) * | 2005-09-01 | 2007-07-13 | 삼성전자주식회사 | 화상형성시스템 및 화상 형성 방법 |
| US8400775B2 (en) * | 2007-07-06 | 2013-03-19 | GM Global Technology Operations LLC | Capacitor with direct DC connection to substrate |
| MX2011000861A (es) * | 2008-07-23 | 2011-06-21 | Hanmi Holdings Co Ltd | Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales. |
| RU2011126338A (ru) * | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | Стабильные композиции антител и способы их стабилизации |
-
2010
- 2010-07-14 KR KR1020100067796A patent/KR101337797B1/ko not_active Expired - Fee Related
-
2011
- 2011-07-14 AR ARP110102545A patent/AR082223A1/es not_active Application Discontinuation
- 2011-07-14 WO PCT/KR2011/005194 patent/WO2012008779A2/en not_active Ceased
- 2011-07-14 BR BR112013000902-0A patent/BR112013000902A2/pt not_active IP Right Cessation
- 2011-07-14 JP JP2013519600A patent/JP5946448B2/ja not_active Expired - Fee Related
- 2011-07-14 RU RU2013106276A patent/RU2623026C2/ru not_active IP Right Cessation
- 2011-07-14 CA CA2805228A patent/CA2805228C/en not_active Expired - Fee Related
- 2011-07-14 TW TW100125060A patent/TWI459961B/zh not_active IP Right Cessation
- 2011-07-14 US US13/809,783 patent/US9061072B2/en not_active Expired - Fee Related
- 2011-07-14 ES ES11807064.8T patent/ES2673022T3/es active Active
- 2011-07-14 AU AU2011277203A patent/AU2011277203B2/en not_active Ceased
- 2011-07-14 EP EP11807064.8A patent/EP2593084B1/en not_active Not-in-force
-
2013
- 2013-01-14 IL IL224225A patent/IL224225B/en active IP Right Grant
-
2018
- 2018-03-20 AR ARP180100643A patent/AR113034A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2593084B1 (en) | 2018-03-14 |
| EP2593084A2 (en) | 2013-05-22 |
| KR101337797B1 (ko) | 2013-12-06 |
| US9061072B2 (en) | 2015-06-23 |
| CA2805228C (en) | 2019-05-07 |
| RU2013106276A (ru) | 2014-08-20 |
| TWI459961B (zh) | 2014-11-11 |
| AR113034A2 (es) | 2020-01-22 |
| AU2011277203B2 (en) | 2015-11-12 |
| CN103068366A (zh) | 2013-04-24 |
| WO2012008779A3 (en) | 2012-05-24 |
| ES2673022T3 (es) | 2018-06-19 |
| AU2011277203A1 (en) | 2013-02-28 |
| RU2623026C2 (ru) | 2017-06-21 |
| AR082223A1 (es) | 2012-11-21 |
| CA2805228A1 (en) | 2012-01-19 |
| TW201215404A (en) | 2012-04-16 |
| BR112013000902A2 (pt) | 2020-08-25 |
| EP2593084A4 (en) | 2014-11-05 |
| US20130115231A1 (en) | 2013-05-09 |
| JP5946448B2 (ja) | 2016-07-06 |
| WO2012008779A2 (en) | 2012-01-19 |
| JP2013531034A (ja) | 2013-08-01 |
| KR20120007182A (ko) | 2012-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL224225B (en) | Liquid formulation of long-acting human growth hormone conjugate | |
| IL251318B (en) | Long-acting preparations containing insulin | |
| ZA201301717B (en) | Liquid agricultural formulations of improved stability | |
| ZA201400616B (en) | Methods and devices for drug delivery to ocular tissue using microneedle | |
| PL2877158T3 (pl) | Ciekła formulacja długo działającego koniugatu peptydu insulinotropowego | |
| PL2643010T3 (pl) | Biologicznie aktywny kompleks i jego otrzymywanie | |
| PL2877157T3 (pl) | Ciekły preparat długo działającego koniugatu insuliny | |
| IL226231A0 (en) | A formulation of lacosamide that is administered once a day | |
| EP2547351A4 (en) | PHARMACEUTICAL COMPOSITIONS OF GROWTH HORMONE SECRETAGOGUE RECEPTOR LIGANDS | |
| IL244769A0 (en) | A long-acting human growth hormone conjugate preparation | |
| EP2533800A4 (en) | LIQUID FORMULATION FROM A FOLLICLE STIMULATING HORMONE | |
| ZA201205385B (en) | Stable growth hormone compounds | |
| AP2012006597A0 (en) | Stable ready to use injectable paracetamol formulation | |
| HUP1000284A3 (en) | Use of derivatives of pgf1-alpha for preparation of medicament for reducing inflammation | |
| GB0813004D0 (en) | Stable therapeutic formulation of human growth hormone | |
| RS20100352A3 (en) | METHOD OF PREPARATION AND USE OF PHARMACOLOGICAL ACTIVE N-CARBAMYLMETHYL-4 (R) -Phenyl-2-Pyrrolidinone | |
| ZA201404698B (en) | Use of growth hormone fragments | |
| GB201019937D0 (en) | Biologically active complex and its preparation | |
| PT3824876T (pt) | Formulações de longa ação de insulinas | |
| TWM388210U (en) | Line structure of grass weeder | |
| TWM390651U (en) | Growing device of scallion stalk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |